Seroquel
(Quetiapine)ApprovedSmall molecule
Quetiapine is used to treat schizophrenia, bipolar disorder, and depression. It works by helping to balance certain chemicals in the brain that affect mood and thinking.[2] Seroquel is currently approved and in use across 32 indications[4].[1]
Seroquel is one of 490 small molecule programs targeting Bipolar Disorder. It is currently in Approved.
32
Indications
255
Total Trials
9
Active Trials
489
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 32 indications
Competition
Competitive Landscape
174 competitors in Schizophrenia
#DrugCompanyPhaseTrials
1Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Ozempic
Novo NordiskPreclinical
Resotran
TakedaPreclinical
Inapsine
Jazz PharmaceuticalsPreclinical
Depakote
AbbViePreclinical
Ibrance
PfizerPreclinical
Lunesta
Akero TherapeuticsPreclinical
Luvox
SSolvay Pharmaceuticals
Preclinical
Catapres
Boehringer IngelheimPreclinical
Persantine
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Schizophrenia25 trials
Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia
Completed·—·Phase 4·NCT01164059·149 enrolled
Show 22 more trials
A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia
Completed·—·N/A·NCT02192723·550 enrolled
Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia
Completed·—·Phase 4·NCT00208143·20 enrolled
Quetiapine Decreases Smoking in Patients With Chronic Schizophrenia
Unknown status·—·N/A·NCT00231101·40 enrolled
Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
Completed·—·Phase 4·NCT00156715·23 enrolled
Bipolar Disorder14 trials
Sequential Multiple Assignment Treatment for Bipolar Disorder
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 4·NCT01588457·112 enrolled
Show 11 more trials
Seroquel ® in Patients With Bipolar Disorder in Remission With Signs of Impaired Impulse Control
Unknown status·—·N/A·NCT05098353·30 enrolled
TIA10 trials
Bioequivalence Study of Quetiapine Fumarate Tablets 300 mg Under Fasting Condition
Completed·—·Phase 1·NCT01566487·54 enrolled
Show 7 more trials
Delirium8 trials
A Double-blind, Randomized, Controlled Trial of Quetiapine Versus Haloperidol for the Treatment of Delirium
Terminated·—·Phase 3·NCT00954603·52 enrolled
Quetiapine in Prevention of Delirium
Completed·—·Phase 2·NCT05793632·90 enrolled
Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of Delirium
Completed·—·Phase 3·NCT01811459·107 enrolled
Show 5 more trials
Bipolar Depression8 trials
Show 5 more trials
74 more indications
Major Depressive Disorder7 trials
Show 4 more trials
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
Recruiting·—·Phase 3·NCT05603104·1,254 enrolled
Schizoaffective Disorder6 trials
Show 3 more trials
Depression6 trials
Psychosis6 trials
Show 3 more trials
Insomnia5 trials
Show 2 more trials
Generalized Anxiety Disorder5 trials
Social Anxiety Disorder3 trials
Adult3 trials
Treatment Resistant Depression3 trials
Antipsychotics3 trials
Medication3 trials
Comparing Antipsychotic Medications in LBD Over Time
Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 4·NCT05590637·94 enrolled
Obsessive-Compulsive Disorder3 trials
Treatment3 trials
Efficacy and Safety3 trials
Bipolar I Disorder3 trials
Agitation2 trials
Fibromyalgia2 trials
Interaction2 trials
Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study
Completed·—·Phase 1·NCT02051387·74 enrolled
Anorexia Nervosa2 trials
Anxiety Disorder2 trials
Quetiapine Augmentation for Primary Anxiety Disorder or Mood Disorders With Co-morbid Anxiety Symptoms
Completed·—·Phase 4·NCT00912535·39 enrolled
Post-Traumatic Stress Disorder2 trials
Quetiapine Treatment for Post-Traumatic Stress Disorder (PTSD)
Completed·—·Phase 4·NCT00237393·80 enrolled
Cannabis Dependence2 trials
Postpartum Depression2 trials
Oral2 trials
Monotherapy2 trials
Anxiety2 trials
Anxiety in Recovering Opiate Dependence
Terminated·—·Phase 4·NCT00668265·14 enrolled
AIN2 trials
Dementia1 trial
Cognitive impairment1 trial
Psychotropic Drugs1 trial
Aggressive Behavior1 trial
Pneumonia1 trial
Benzodiazepines1 trial
Depressed1 trial
Maintenance Treatment1 trial
Drug Abuse1 trial
Borderline personality disorder1 trial
Obstructive Sleep Apnea1 trial
Functional Bowel Disorder1 trial
First-line Treatment1 trial
Partial Response1 trial
Effectiveness1 trial
Safety and Efficacy1 trial
Sedation1 trial
Cocaine Dependence1 trial
Substance Use Disorders1 trial
Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation
Completed·—·Phase 4·NCT02845453·24 enrolled
Major Depression1 trial
Weight Change1 trial
Chronic Kidney Disease1 trial
Sleep Disorders in Chronic Kidney Disease Patients
Unknown status·—·Phase 1·NCT05240261·60 enrolled
PET1 trial
Using 18F-FPEB PET to Identify mGLUR5 Availability in Affective Disorders
Unknown status·—··NCT05840861·59 enrolled
Treatment Refractory Schizophrenia1 trial
Psychiatric Disorder1 trial
Bipolar II Disorder1 trial
Efficacy1 trial
Regulatory
FDA Approval Timeline[5]
Sep 26, 1997
SEROQUEL
NDA NDA020639
May 17, 2007
SEROQUEL XR
NDA NDA022047
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Seroquel drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Quetiapine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details